Three-year Follow up of GMCSF/bi-shRNA furin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma

Molecular Therapy

Volumn 24, Issue 8, 2016, Pages 1478-1483

  Ghisoli, Maurizio ^a,b,c   Barve, Minal ^a,b   Mennel, Robert ^b,d   Lenarsky, Carl ^b,c   Horvath, Staci ^a   Wallraven, Gladice ^e   Pappen, Beena O ^e   Whiting, Sam ^e   Rao, Donald ^f   Senzer, Neil ^a,e   Nemunaitis, John ^a,b,c,e,f  

^a Mary Crowley Cancer Research Centers   (United States)

^b TEXAS ONCOLOGY   (United States)

^c MEDICAL CITY DALLAS HOSPITAL   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e GRADALIS INC   (United States)

^f Strike Bio Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLASMID DNA; SHORT HAIRPIN RNA;

ADOLESCENT; ADULT; ARTICLE; BONE PAIN; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE COURSE; DNA TRANSFECTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EWING SARCOMA; FATIGUE; FEMALE; FOLLOW UP; HIP PAIN; HUMAN; HUMAN TISSUE; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LUNG CANCER; MALE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; SKIN BRUISING; SURVIVAL TIME; THERAPY DELAY; THORAX PAIN;

EID: 84978628970     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.86     Document Type: Article

References (33)

1. Esiashvili, N, Goodman, M and Marcus, RB Jr (2008). Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol 30: 425-430.
2. http://www.cancer.gov/types/bone/hp/ewing-treatment-pdq. Revised 19 November 2015.
3. Cotterill, SJ, Ahrens, S, Paulussen, M, Jürgens, HF, Voûte, PA, Gadner, H et al. (2000). Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 18: 3108-3114.
4. Stahl, M, Ranft, A, Paulussen, M, Bölling, T, Vieth, V, Bielack, S et al. (2011). Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57: 549-553.
5. Ozaki, T, Hillmann, A, Hoffmann, C, Rübe, C, Blasius, S, Dunst, J et al. (1996). Significance of surgical margin on the prognosis of patients with Ewing's sarcoma. A report from the Cooperative Ewing's Sarcoma Study. Cancer 78: 892-900.
6. Bacci, G, Picci, P, Ferrari, S, Mercuri, M, Brach del Prever, A, Rosito, P et al. (1998). Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase-results of two sequential studies. Cancer 82: 1174-1183.
7. Klingebiel, T, Pertl, U, Hess, CF, Jürgens, H, Koscielniak, E, Pötter, R et al. (1998). Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. Med Pediatr Oncol 30: 269-275.
8. Leavey, PJ and Collier, AB (2008). Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther 8: 617-624.
9. Rodriguez-Galindo, C, Billups, CA, Kun, LE, Rao, BN, Pratt, CB, Merchant, TE et al. (2002). Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer 94: 561-569.
10. Shankar, AG, Ashley, S, Craft, AW and Pinkerton, CR (2003). Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 40: 141-147.
11. Barker, LM, Pendergrass, TW, Sanders, JE and Hawkins, DS (2005). Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 23: 4354-4362.
12. McTiernan, AM, Cassoni, AM, Driver, D, Michelagnoli, MP, Kilby, AM and Whelan, JS (2006). Improving outcomes after relapse in Ewing's sarcoma: analysis of 114 patients from a single institution. Sarcoma 2006: 83548.
13. Bacci, G, Ferrari, S, Longhi, A, Donati, D, De Paolis, M, Forni, C et al. (2003). Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 14: 1654-1659.
14. Hamilton, SN, Carlson, R, Hasan, H, Rassekh, SR and Goddard, K (2015). Long-term outcomes and complications in pediatric Ewing sarcoma. Am J Clin Oncol (epub ahead of print).
15. Rasper, M, Jabar, S, Ranft, A, Jürgens, H, Amler, S and Dirksen, U (2014). The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer 61: 1382-1386.
16. Navid, F, Billups, C, Liu, T, Krasin, MJ and Rodriguez-Galindo, C (2008). Second cancers in patients with the Ewing sarcoma family of tumours. Eur J Cancer 44: 983-991.
17. Merchant, TE, Kushner, BH, Sheldon, JM, LaQuaglia, M and Healey, JH (1999). Effect of low-dose radiation therapy when combined with surgical resection for Ewing sarcoma. Med Pediatr Oncol 33: 65-70.
18. Saylors, RL 3rd, Stine, KC, Sullivan, J, Kepner, JL, Wall, DA, Bernstein, ML et al.; Pediatric Oncology Group. (2001). Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 19: 3463-3469.
19. Wagner, LM, McAllister, N, Goldsby, RE, Rausen, AR, McNall-Knapp, RY, McCarville, MB et al. (2007). Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 48: 132-139.
20. Wagner, LM, Crews, KR, Iacono, LC, Houghton, PJ, Fuller, CE, McCarville, MB et al. (2004). Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 10: 840-848.
21. Wagner, LM (2010). Oral irinotecan for treatment of pediatric solid tumors: ready for prime time Pediatr Blood Cancer 54: 661-662.
22. Wagner, LM, Perentesis, JP, Reid, JM, Ames, MM, Safgren, SL, Nelson, MD Jr et al. (2010). Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer 54: 538-545.
23. Wagner, L, Turpin, B, Nagarajan, R, Weiss, B, Cripe, T and Geller, J (2013). Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. Pediatr Blood Cancer 60: 1447-1451.
24. Casey, DA, Wexler, LH, Merchant, MS, Chou, AJ, Merola, PR, Price, AP et al. (2009). Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 53: 1029-1034.
25. Raciborska, A, Bilska, K, Drabko, K, Chaber, R, Pogorzala, M, Wyrobek, E et al. (2013). Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer 60: 1621-1625.
26. McGregor, LM, Stewart, CF, Crews, KR, Tagen, M, Wozniak, A, Wu, J et al. (2012). Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors. Pediatr Blood Cancer 58: 372-379.
27. Navid, F, Willert, JR, McCarville, MB, Furman, W, Watkins, A, Roberts, W et al. (2008). Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 113: 419-425.
28. Mora, J, Cruz, CO, Parareda, A and de Torres, C (2009). Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol 31: 723-729.
29. Rapkin, L, Qayed, M, Brill, P, Martin, M, Clark, D, George, BA et al. (2012). Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer 59: 854-858.
30. Gaspar, N, Hawkins, DS, Dirksen, U, Lewis, IJ, Ferrari, S, Le Deley, MC et al. (2015). Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33: 3036-3046.
31. Ghisoli, M, Barve, M, Schneider, R, Mennel, R, Lenarsky, C, Wallraven, G et al. (2015). Pilot trial of FANG immunotherapy in Ewing's sarcoma. Mol Ther 23: 1103-1109.
32. Senzer, N, Barve, M, Kuhn, J, Melnyk, A, Beitsch, P, Lazar, M et al. (2012). Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther 20: 679-686.
33. Senzer, N, Barve, M, Nemunaitis, J, Kuhn, J, Melnyk, A, Beitsch, P et al. (2013). Long term follow up: phase I trial of "bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell" immunotherapy (FANG™) in advanced cancer. J Vaccines and Vaccination 4: 209.